表紙
市場調查報告書
商品編碼
1000845

繼發性甲狀旁腺功能亢進症(荷爾蒙失調):藥物正在開發中(2021)

Secondary Hyperparathyroidism (Hormonal Disorders) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 63 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

繼發性甲狀旁腺功能亢進症是由於鈣含量極低導致甲狀旁腺分泌過多的甲狀旁腺激素(PTH)引起的。症狀包括骨骼畸形,骨折,關節腫脹和慢性腎功能衰竭。治療方法包括calsim和激素替代療法。

本報告調查了針對繼發性甲狀旁腺功能亢進症(荷爾蒙失調)正在開發的藥物,全球治療情況,管道療法的評論和發展,用於管道產品的藥物,它提供了全面的信息,包括概況,領先公司的評論和最新新聞。對繼發性甲狀旁腺功能亢進症的治療。

目錄

  • 簡介
  • 全球市場直接報告範圍
  • 繼發性甲狀旁腺功能亢進症-概述
  • 繼發性甲狀旁腺功能亢進症-治療的發展
  • 管道概述
  • 公司管道
  • 公司正在開發的產品
  • 繼發性甲狀旁腺功能亢進症治療評估
  • 按目標評估
  • 通過作用機制進行評估
  • 按管理途徑評估
  • 按分子類型評估
  • 繼發性甲狀旁腺功能亢進-參與治療開發的公司
  • Amgen Inc
  • Cinkate Corp
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novadiol Inc
  • OPKO Health Inc
  • Scohia Pharma Inc
  • TaiRx Inc
  • Vidasym Inc
  • 繼發性甲狀旁腺功能亢進症-藥物特徵
  • Calcifedioldiol ER-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • Cinacalcet-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • CK-15-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • CTA-091-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • Dendoclean-藥品檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 鹽酸依格列酮-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • evocalcet-drug檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • LNP-1892-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • SCO-006-藥品檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • upacicalcet-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • VS-105-藥品簡介
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 繼發性甲狀旁腺功能亢進症-休眠項目
  • 繼發性甲狀旁腺功能亢進症停產的產品
  • 繼發性甲狀旁腺功能亢進症-產品開發的里程碑
  • 精選新聞和新聞稿
  • 2020年12月21日:在日本推出了鈣模擬藥透析脈搏單抗輸液注射器
  • 2020年6月29日:ONO:在日本獲得了鈣模擬藥透析脈搏單抗輸液注射器的生產和銷售許可。
  • 2020年3月25日:OPKO Health:兩項正在進行的RAYALDEE研究的中期結果
  • 2018年9月4日:OPKO:RAYALDEE在透析患者中□□進行2期臨床試驗
  • 2018年7月16日:OPKO:合作夥伴Vifor Fresenius在加拿大獲得RAYAL DEE營銷批准
  • 2018年5月22日:Kyowa Hakko Kirin:推出ORKEDIA平板電腦作為日本接受維持性透析的患者繼發性甲狀旁腺功能亢進症的治療方法
  • 2018年3月23日:Kyowa Hakko Kirin:在日本進行維持性透析的患者中獲得ORKEDIA片(Evocal set)用於繼發性甲狀旁腺功能亢進症的治療的批准。
  • 2017年11月6日:Kyowa Hakko Kirin:美國腎臟病學會2017年腎臟週在日本宣佈Evocal Set的3期臨床試驗結果
  • 2017年6月22日:OPKOHealth:宣佈更新CKD-MBD的KDIGO臨床實踐指南
  • 2017年6月5日:OPKOHealth:為RAYALDEE提供商業更新
  • 2017年4月27日:Kyowa Hakko Kirin:提交了批准日本維持性透析患者繼發性甲狀旁腺功能亢進用聲波套件(KHK7580)的申請
  • 2017年2月15日:啟動靜脈注射用於PARSABIV透析的鈣模擬藥物,用於治療血液透析患者的繼發性甲狀旁腺功能亢進
  • 2017年2月7日:OPKOHealth:將Thomas Nusbickel提升為腎臟部門首席商務官
  • 2017年2月7日:FDA:安進(Amgen)的帕沙維布(Etelcalcetide)批准。
  • 2017年1月31日:Kyowa Hakko Kirin:在日本宣佈KHK7580繼發性甲狀旁腺功能亢進症三期臨床試驗的主要結果
  • 附錄
  • 調查方法
  • 調查範圍
  • 二次調查
  • 初步調查
  • 專家小組驗證
  • 聯繫我們
  • 免責聲明
目錄
Product Code: GMDHC12792IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Drugs in Development, 2021, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1, 3 and 3 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Secondary Hyperparathyroidism - Overview
  • Secondary Hyperparathyroidism - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Secondary Hyperparathyroidism - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Cinkate Corp
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novadiol Inc
  • OPKO Health Inc
  • Scohia Pharma Inc
  • TaiRx Inc
  • Vidasym Inc
  • Secondary Hyperparathyroidism - Drug Profiles
  • calcifediol ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cinacalcet - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CK-15 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTA-091 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Dendocrin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • etelcalcetide hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • evocalcet - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LNP-1892 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SCO-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • upacicalcet - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VS-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Secondary Hyperparathyroidism - Dormant Projects
  • Secondary Hyperparathyroidism - Discontinued Products
  • Secondary Hyperparathyroidism - Product Development Milestones
  • Featured News & Press Releases
  • Dec 21, 2020: Launch of Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent in Japan
  • Jun 29, 2020: ONO receives manufacturing and marketing approval in Japan for Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent
  • Mar 25, 2020: OPKO Health reports interim results for two ongoing RAYALDEE studies
  • Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients
  • Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
  • May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
  • Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
  • Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology
  • Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
  • Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE
  • Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan
  • Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
  • Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer
  • Feb 07, 2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
  • Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Secondary Hyperparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Secondary Hyperparathyroidism - Pipeline by Amgen Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by Cinkate Corp, 2021
  • Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, 2021
  • Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, 2021
  • Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Secondary Hyperparathyroidism - Pipeline by Novadiol Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by Scohia Pharma Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by TaiRx Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by Vidasym Inc, 2021
  • Secondary Hyperparathyroidism - Dormant Projects, 2021
  • Secondary Hyperparathyroidism - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Secondary Hyperparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • umber of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021